{"created":"2023-06-19T07:26:01.921210+00:00","id":14254,"links":{},"metadata":{"_buckets":{"deposit":"072eded8-716c-46c8-9030-19ca43f4b78e"},"_deposit":{"created_by":116,"id":"14254","owners":[116],"pid":{"revision_id":0,"type":"depid","value":"14254"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00014254","sets":["212:263:303"]},"author_link":["32832","32839","32830","32831","32834","32838","32836","32833","32840","32837","32842","32841","32829","32835"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"205031212097417","bibliographicVolumeNumber":"8","bibliographic_titles":[{},{"bibliographic_title":"SAGE Open Medicine","bibliographic_titleLang":"en"}]}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis","subitem_title_language":"en"}]},"item_type_id":"3","owner":"116","path":["303"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-03-03"},"publish_date":"2021-03-03","publish_status":"0","recid":"14254","relation_version_is_last":true,"title":["Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis"],"weko_creator_id":"116","weko_shared_id":-1},"updated":"2023-06-19T07:44:39.575648+00:00"}